Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
AMP + diphosphate + L-methionyl-tRNAMet
ATP + L-methionine + tRNAMet
-
-
-
r
ATP + (S)-2-aminohex-5-enoic acid + tRNAMet
AMP + diphosphate + (S)-2-aminohex-5-enoyl-tRNAMet
1850fold reduced activity compared to L-methionine
-
?
ATP + (S)-2-aminohex-5-enoic acid + tRNAMet
AMP + diphosphate + 2(S)-aminohex-5-enoyl-tRNAMet
-
-
?
ATP + (S)-2-aminohex-5-ynoic acid + tRNAMet
AMP + diphosphate + 2(S)-aminohex-5-ynoyl-tRNAMet
500fold reduced activity compared to L-methionine
-
?
ATP + azidonorleucine + tRNAMet
AMP + diphosphate + azidonorleucinyl-tRNAMet
MetRS SLL-mutant
-
?
ATP + azidonorleucine + tRNAMet
AMP + diphosphate + azidonorleucyl-tRNAMet
activity of mutant L13G, overview
-
?
ATP + L-homocysteine + tRNAMet
?
-
edition and aminoacylation by cytoplasmic and mitochondrial isozyme
-
?
ATP + L-methionine + tRNA fraction from Saccharomyces cerevisiae
?
-
-
?
ATP + L-methionine + tRNAArg(CCU)
?
tRNA mismethionylation
-
?
ATP + L-methionine + tRNAAsp
AMP + diphosphate + L-methionyl-tRNAAsp
only the wild-type enzyme, not the C-terminally deleted enzyme mutant
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
ATP + L-methionine + tRNAThr(CGU)
?
tRNA mismethionylation
-
?
ATP + L-norleucine + tRNAMet
AMP + diphosphate + L-norleucyl-tRNAMet
ATP + L-trans-alpha-crotylglycine + tRNAMet
AMP + diphosphate + L-trans-alpha-crotylglycyl-tRNAMet
4700fold reduced activity compared to L-methionine
-
?
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
ATP + methionine + hydroxylamine
methionine hydroxamate + AMP + diphosphate
ATP + selenomethionine + tRNAMet
AMP + diphosphate + selenomethionyl-tRNAMet
CoA + L-methionine
Met-S-CoA
-
-
-
?
additional information
?
-
ATP + L-methionine + tRNAMet

AMP + diphosphate + L-methionyl-tRNAMet
-
the MetRS specificity for methionine and conformity with the identity rules for tRNAMet for archea/eukarya, anticodon binding site, overview
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
functional idiosyncrasies of the viral MetRS, activity with Escherichia coli native tRNAMet and initiator tRNAMet, and Saccharomyces cerevisiae native tRNAMet and initiator tRNAMet, overview, the MetRS specificity for methionine and recognition of the tRNAMet acceptor stem show conformity with the identity rules for tRNAMet for archea/eukarya, overview
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
structural basis for anticodon recognition by the enzyme, catalytic Rossmann fold domain
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
essentiality of the metS1, nonessentiality of the metS2 for vegetative growth
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
MetRS specifically binds tRNAMet and catalyzes the synthesis of methionyl-tRNAMet. The C-terminal appended domain causes a slow release of aminoacyl-tRNA and establishes a limiting step in the global aminoacylation reaction
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
also utilizes both subtypes of Escherichia coli tRNAMet
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
active site analysis and docking study, overview. Key residues are His53, Asp51 and Lys56 consistently forming H-bonding interactions with the carboxylic acid moiety of methionine. Ile12 forms a hydrogen bond with this moiety in different dockings and the residues Ile224, Val226 and Ala230 form a hydrophobic pocket
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
active site analysis and docking study, overview. Key residues are His53, Asp51 and Lys56 consistently forming H-bonding interactions with the carboxylic acid moiety of methionine. Ile12 forms a hydrogen bond with this moiety in different dockings and the residues Ile224, Val226 and Ala230 form a hydrophobic pocket
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
binding of L-methionine induces conformational changes of the active site of the enzyme, amino acid residues Y15 and W253 are important for the strength of binding, H301 is responsible for the specific recognition of the sulfur atom of methionine
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
covalent binding of methionine to the tRNAMet
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
formation of an methionine adenylate reaction intermediate
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
reduced activity with L-methionine analogues, overview, two-step reaction, the first step, the aminoacylation, is reversible, the seconde, the transfer reaction, is not
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
substrate editing mechanism, L-methionine is bound to a hydrophobic pocket formed by amino acid residues W253, Y15, A256, P257, L13, A12, I297, Y260, H301, and W305 around the side-chain
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
L-methionine and methionine analogue substrates are incorporated in proteins, overview
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
conformation of tRNA and the recognition of anticodon by MetRS, hydrogen bonding patterns, interactions at the active site, overview
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
residues L13, P257, Y260, and H301 are involved in the Met binding site
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
two-step reaction mechanism, enzyme forms the reaction intermediate L-methionyl-adenylate, which covalently methionylates the enzyme at the epsilon-amino group of a lysine residue, inducing structural modifcation, 4.3 and 2.2 mol of Met are incorporated by 1 mol of wild-type enzyme and truncated mutant enzyme, respectively
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
protein biosynthesis in archaea is initiated with methionine not with formylmethionine
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
protein biosynthesis in archaea is initiated with methionine not with formylmethionine
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
the C-terminal ancillary RNA-binding domain is important for activity and has dual function provided by 2 structural motifs: 1. the helix-turn-helix HTH motif, which confers rate-limiting dissociation of the aminoaclyted tRNA from the enzyme, and 2. the KGKKKK lysine-rich cluster LRC, which is probably involved in accelerating the association step of deacylated tRNA
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
the nucleolar located enzyme is related to rRNA synthesis, the cytoplasmic enzyme is involved in protein biosynthesis
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
human mitochondrial wild-type and mutant mtRNAs: T5048 deletion, and T5052C or T5012A point mutations, initiator tRNA from Escherichia coli, tRNAMet from Bos taurus
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
binding structures of substrates and products, overview
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
Lupinus sp.
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
also utilizes tRNAMet from Escherichia coli
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
analysis of methionine and adenosine binding to MetRS, catalytic domain structure, overview. The KMSKS domain, residues 293-350, or stem contact fold domain, with a beta-alpha-alpha-beta-alpha topology domain, connects the catalytic domain with the anticodon domain, KMSKS domain conformation and structure, modelling, overview
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
the EMAPII-like C-terminal appendix domain provides the enzyme with non-specific tRNA binding properties, the deleted enzyme form missing this domain is therefore more specific and shows a 10fold lower Km for the tRNA substrate, enzyme is also active with tRNAMet from Saccharomyces cerevisiae
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
dimerization of the enzyme is required for affinity to tRNAMet
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
tRNA anticodon binding site structure
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
initiator and elongation tRNAMet, cytoplasmic and mitochondrial isozyme
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
covalent binding of methionine to the tRNAMet
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
substrates: prokaryotic, chloroplastic, cytoplasmic (initiator not non-initiator)
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-norleucine + tRNAMet

AMP + diphosphate + L-norleucyl-tRNAMet
1050fold reduced activity compared to L-methionine
-
?
ATP + L-norleucine + tRNAMet
AMP + diphosphate + L-norleucyl-tRNAMet
-
-
-
?
ATP + L-valine + tRNAMetG34C36

AMP + diphosphate + L-valyl-tRNAMetG34C36
-
anticodon mutant initiator tRNAMet, reduced reverse, i.e. deacetylation, reaction
-
r
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
-
CAU to GAC anticodon mutant initiator tRNAMet, reduced reverse, i.e. deacetylation, reaction
-
r
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
-
anticodon mutant initiator tRNAMet, reduced reverse, i.e. deacetylation, reaction
-
r
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
-
CAU to GAC anticodon mutant initiator tRNAMet, reduced reverse, i.e. deacetylation, reaction
-
r
ATP + methionine + hydroxylamine

methionine hydroxamate + AMP + diphosphate
-
-
-
?
ATP + methionine + hydroxylamine
methionine hydroxamate + AMP + diphosphate
-
-
-
?
ATP + selenomethionine + tRNAMet

AMP + diphosphate + selenomethionyl-tRNAMet
-
-
-
?
ATP + selenomethionine + tRNAMet
AMP + diphosphate + selenomethionyl-tRNAMet
-
-
-
?
ATP + selenomethionine + tRNAMet
AMP + diphosphate + selenomethionyl-tRNAMet
-
-
-
?
additional information

?
-
-
mimivirus aminoacyl-tRNA synthetases function as regular translation enzymes in infected amoebas
-
?
additional information
?
-
Met-tRNA anticodon interactions with the MetRS homology model, overview
-
?
additional information
?
-
-
Met-tRNA anticodon interactions with the MetRS homology model, overview
-
?
additional information
?
-
Met-tRNA anticodon interactions with the MetRS homology model, overview
-
?
additional information
?
-
-
homocysteine thiolactone is formed as a product of an error-editing reaction, which prevents incorporation of homocysteine into tRNA and protein (not enzyme from temperature-sensitive mutant of CHO-cells, at non-permissive temperature)
-
?
additional information
?
-
-
homocysteine thiolactone is formed as a product of an error-editing reaction, which prevents incorporation of homocysteine into tRNA and protein (not enzyme from temperature-sensitive mutant of CHO-cells, at non-permissive temperature)
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
?
additional information
?
-
-
enzyme also performs the ATP-diphosphate exchange reaction
-
?
additional information
?
-
-
the enzyme also performs the ATP-diphosphate exchange reaction
-
?
additional information
?
-
the enzyme also performs the ATP-diphosphate exchange reaction
-
?
additional information
?
-
-
L-homocysteine is a natural competitor to L-methionine, its activation by the enzyme is prevented by a proof-reading mechanism, structural requirements are determined form the crystal structure
-
?
additional information
?
-
-
phylogenetic analysis
-
?
additional information
?
-
-
modeling of the structure of a complex consisting of MetRS, tRNA, and activated methionine, molecular dynamics simulations, evaluation of the equilibrated structure of the complex and the cross-correlations between the residues in MetRS, analysis of communication between the activation site and the anticodon recognition site, overview
-
?
additional information
?
-
-
no activity with L-methionyl-tRNALys
-
?
additional information
?
-
-
enzyme also performs the ATP-diphosphate exchange reaction
-
?
additional information
?
-
-
no activity with the CAU to CUA initiator tRNAMet mutant in vivo
-
?
additional information
?
-
-
no activity with the CAU to CUA initiator tRNAMet mutant in vivo
-
?
additional information
?
-
-
homocysteine thiolactone is formed as a product of an error-editing reaction, which prevents incorporation of homocysteine into tRNA and protein (not enzyme from temperature-sensitive mutant of CHO-cells, at non-permissive temperature)
-
?
additional information
?
-
the enzyme performs ATP/diphosphate exchange in absence of substrates
-
?
additional information
?
-
-
the enzyme performs ATP/diphosphate exchange in absence of substrates
-
?
additional information
?
-
Lupinus sp.
-
methionine-dependent ATP-diphosphate exchange
-
?
additional information
?
-
-
homocysteine thiolactone is formed as a product of an error-editing reaction, which prevents incorporation of homocysteine into tRNA and protein (not enzyme from temperature-sensitive mutant of CHO-cells, at non-permissive temperature)
-
?
additional information
?
-
-
phylogenetic analysis
-
?
additional information
?
-
-
no other amino acid than methionine is activated in ATP-diphosphate exchange
-
?
additional information
?
-
-
enzyme forms A and B show differences in their capacity to recognize the cognate tRNAs
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
?
additional information
?
-
binding of the enzyme to the split 3'-half tRNA species is stronger than to that of the 5'-half species
-
?
additional information
?
-
-
binding of the enzyme to the split 3'-half tRNA species is stronger than to that of the 5'-half species
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
?
additional information
?
-
-
also catalyzes L-homocysteine, L-selenocysteine and norleucine-dependent ATP-diphosphate exchange
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
?
additional information
?
-
-
also catalyzes L-homocysteine, L-selenocysteine and norleucine-dependent ATP-diphosphate exchange
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
?
additional information
?
-
-
homocysteine thiolactone is formed as a product of an error-editing reaction, which prevents incorporation of homocysteine into tRNA and protein (not enzyme from temperature-sensitive mutant of CHO-cells, at non-permissive temperature)
-
?
additional information
?
-
-
the isozymes also perform the ATP-diphosphate exchange reaction
-
?
additional information
?
-
MetRS interacts with the accessory protein Arc1p, interaction mode and structure, overview
-
?
additional information
?
-
-
MetRS interacts with the accessory protein Arc1p, interaction mode and structure, overview
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
?
additional information
?
-
-
also catalyzes selenomethionine- and selenoethionine-dependent ATP-diphosphate exchange
-
?
additional information
?
-
-
no other amino acid than methionine is activated in ATP-diphosphate exchange
-
?
additional information
?
-
-
methionine-dependent ATP-diphosphate exchange
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + azidonorleucine + tRNAMet
AMP + diphosphate + azidonorleucyl-tRNAMet
activity of mutant L13G, overview
-
-
?
ATP + L-homocysteine + tRNAMet
?
-
edition and aminoacylation by cytoplasmic and mitochondrial isozyme
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
additional information
?
-
ATP + L-methionine + tRNAMet

AMP + diphosphate + L-methionyl-tRNAMet
-
the MetRS specificity for methionine and conformity with the identity rules for tRNAMet for archea/eukarya, anticodon binding site, overview
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
essentiality of the metS1, nonessentiality of the metS2 for vegetative growth
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
MetRS specifically binds tRNAMet and catalyzes the synthesis of methionyl-tRNAMet. The C-terminal appended domain causes a slow release of aminoacyl-tRNA and establishes a limiting step in the global aminoacylation reaction
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
L-methionine and methionine analogue substrates are incorporated in proteins, overview
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
protein biosynthesis in archaea is initiated with methionine not with formylmethionine
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
protein biosynthesis in archaea is initiated with methionine not with formylmethionine
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
the nucleolar located enzyme is related to rRNA synthesis, the cytoplasmic enzyme is involved in protein biosynthesis
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
r
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
initiator and elongation tRNAMet, cytoplasmic and mitochondrial isozyme
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-methionine + tRNAMet
AMP + diphosphate + L-methionyl-tRNAMet
-
-
-
?
ATP + L-valine + tRNAMetG34C36

AMP + diphosphate + L-valyl-tRNAMetG34C36
-
CAU to GAC anticodon mutant initiator tRNAMet, reduced reverse, i.e. deacetylation, reaction
-
r
ATP + L-valine + tRNAMetG34C36
AMP + diphosphate + L-valyl-tRNAMetG34C36
-
CAU to GAC anticodon mutant initiator tRNAMet, reduced reverse, i.e. deacetylation, reaction
-
r
additional information

?
-
-
mimivirus aminoacyl-tRNA synthetases function as regular translation enzymes in infected amoebas
-
-
?
additional information
?
-
-
L-homocysteine is a natural competitor to L-methionine, its activation by the enzyme is prevented by a proof-reading mechanism, structural requirements are determined form the crystal structure
-
?
additional information
?
-
-
phylogenetic analysis
-
?
additional information
?
-
-
no activity with the CAU to CUA initiator tRNAMet mutant in vivo
-
?
additional information
?
-
-
no activity with the CAU to CUA initiator tRNAMet mutant in vivo
-
?
additional information
?
-
-
phylogenetic analysis
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R,3S)-3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) cyclohexanamine
-
(E)-N-[3-(1H-benzimidazol-1-yl)propyl]-1-(3,5-dimethoxyphenyl)methanimine
-
-
(E)-N-[3-(1H-benzimidazol-1-yl)propyl]-1-(4-bromophenyl)methanimine
-
-
(E)-N-[3-(1H-benzimidazol-1-yl)propyl]-1-(4-chlorophenyl)methanimine
-
-
(E)-N-[3-(1H-benzimidazol-1-yl)propyl]-1-(4-methoxyphenyl)methanimine
-
-
(E)-N-[3-(1H-benzimidazol-1-yl)propyl]-1-phenylmethanimine
-
-
(R)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) piperidin-3-amine
-
(R)-1-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) pyrrolidin-3-amine
-
(S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) piperidin-3-amine
-
(S)-1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorophenyl) piperidine-3-carboxamide
-
(S)-1-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) pyrrolidin-3-amine
-
(S)-2-amino-heptanoic acid
L-methionine analogue, competitive
(S)-2-aminohex-5-enoic acid
L-methionine analogue, competitive
(S)-2-aminohex-5-ynoic acid
L-methionine analogue, competitive
(S)-3,5-dichloro-N-(1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)benzamide
-
(S)-5-chloro-2-(3-((3,5-dichlorobenzyl)oxy)piperidin-1-yl)-1H-imidazo[4,5-b]pyridine
-
1,4-anhydro-2-bromo-2,3,5-trideoxy-1-(1-fluoroethenyl)-3-methyl-5-([3-[(4-oxo-1,4-dihydroquinolin-2-yl)amino]propyl]amino)-1-thiopentitol
-
-
1-(3-(1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl) ethanone
-
1-(3-(4-chloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl) ethanone
-
1-(3-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone
-
1-(3-(5-chloro-1H-benzo[d]imidazol-2-yl) piperidin-1-yl)-2-(3,5-dichlorophenyl) ethanone
-
1-(3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone
-
1-(3-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-2-(3,5-dichlorophenyl)ethanone
-
1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)azepan-3-amine
-
1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)azetidin-3-amine
-
1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)piperidin-3-amine
-
1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl)piperidin-4-amine
-
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-3-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-4-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-3-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-4-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[2-(4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[3-[(3,5-dibromobenzyl)amino]propyl]-3-phenylurea
1-[[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
1-[[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
2-((5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)thio)-N-(3,5-dichlorobenzyl) ethanamine
-
2-(1H-indol-3-yl)-1,4-dihydro-2H-3,1-benzoxazine
-
-
2-(1H-indol-3-yl)-5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane
-
-
2-(2,3-dihydroquinolin-2-yl)phenol
-
-
2-(2,4-dichlorophenyl)-6-methylquinoline
-
-
2-(2,4-dichlorophenyl)quinoline
-
-
2-(2,6-difluorophenyl)-5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane
-
-
2-(2-bromophenyl)-6-methyl-2,3-dihydroquinoline
-
-
2-(2-butyl-4-chloro-1-(4-nitrobenzyl)-1H-imidazol-5-yl)-2,4-dihydro-1Hbenzo[d][1,3]oxazine
-
-
2-(2-butyl-4-chloro-1-(4-phenoxybenzyl)-1H-imidazol-5-yl)-5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane
-
-
2-(2-butyl-4-chloro-1H-imidazol-5-yl)-1,4-dihydro-2H-3,1-benzoxazine
-
-
2-(2-butyl-4-chloro-1H-imidazol-5-yl)-5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane
-
-
2-(3,5-dichlorophenyl)-1-(3-(5-fluoro-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)ethanone
-
2-(3-[[(4,6-dichloro-1H-indol-2-yl)methyl]amino]propoxy)quinazolin-4(1H)-one
-
-
2-(4-bromophenyl)-5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecane
-
-
2-([2-[([2-[(2-fluorophenyl)methoxy]naphthalen-1-yl]methyl)amino]ethyl]amino)ethan-1-ol
-
-
2-([2-[([2-[(4-fluorophenyl)methoxy]naphthalen-1-yl]methyl)amino]ethyl]amino)ethan-1-ol
-
-
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-4H-chromen-4-one
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
2-([3-[(2,3-dichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
77.9% inhibition at 50 nM
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(2,4-dichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
87.1% inhibition at 50 nM
2-([3-[(2,5-dichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
93.1% inhibition at 50 nM
2-([3-[(2,6-dichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
51.3% inhibition at 50 nM
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(2-chlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
31.8% inhibition at 50 nM
2-([3-[(3,4-dichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
91.7% inhibition at 50 nM
2-([3-[(3,4-dichlorobenzyl)amino]propyl]thio)quinolin-4(1H)-one
2-([3-[(3,5-dibromo-2-ethoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
2-([3-[(3,5-dibromo-2-methoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1H-indole-3-carbonitrile
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-6-phenylpyrimidin-4(1H)-one
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinolin-4(1H)-one
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-d]pyrimidin-4(1H)-one
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(3,5-dichlorobenzyl)amino]propyl]amino)-4a,8a-dihydroquinolin-4(1H)-one
-
2-([3-[(3,5-dichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
99.2% inhibition at 50 nM
2-([3-[(3,5-difluorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
45.8% inhibition at 50 nM
2-([3-[(3,5-dimethoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
35.3% inhibition at 50 nM
2-([3-[(3,5-dimethylbenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
91.1% inhibition at 50 nM
2-([3-[(3-bromobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
82.7% inhibition at 50 nM
2-([3-[(3-chlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
97.3% inhibition at 50 nM
2-([3-[(3-ethoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
19.1% inhibition at 50 nM
2-([3-[(4-chlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
52.0% inhibition at 50 nM
2-([3-[(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
2-chloro-4-[(4-methoxybenzyl)oxy]quinoline
2-[(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)amino]quinazolin-4(1H)-one
-
-
2-[(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)amino]quinolin-4(1H)-one
-
2-[(3-[[(4,6-dichloro-1H-indol-2-yl)methyl](methyl)amino]propyl)amino]quinazolin-4(1H)-one
-
-
2-[(3-[[(4,6-dichloro-1H-indol-2-yl)methyl]amino]propyl)amino]quinazolin-4(1H)-one
-
DDDD806905, highly potent inhibitor, competitive inhibition with respect to L-methionine
2-[(3-[[3,5-bis(trifluoromethyl)benzyl]amino]propyl)amino]quinolin-4(1H)-one
-
36.9% inhibition at 50 nM
2-[(3-[[3-(trifluoromethoxy)benzyl]amino]propyl)amino]quinolin-4(1H)-one
-
56.5% inhibition at 50 nM
2-[([2-[(4-fluorophenyl)methoxy]naphthalen-1-yl]methyl)amino]ethan-1-ol
-
-
2-[([3-[(1H-benzimidazol-2-yl)amino]propyl]amino)methyl]-6-(trifluoromethyl)-1H-indole-4-peroxol
-
-
2-[2-allyloxy-3-(3,4-dichlorobenzylamino)-propylamino]-1H-quinolin-4-one
-
-
2-[2-amino-3-(3,4-dichlorobenzylamino)-propylamino]-1H-quinolin-4-one tri(trifluoroacetic acid)
-
-
2-[2-benzyloxy-3-(3,4-dichlorobenzylamino)-propylamino]-1H-quinolin-4-one
-
-
2-[2-[([3-[(1H-benzimidazol-2-yl)amino]propyl]amino)methyl]-4,6-dichloro-1H-indol-1-yl]ethan-1-ol
-
-
2-[3-(3,4-dichlorobenzylamino)-1-hydroxymethylpropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-dimethylaminopropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-ethoxypropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-hydroxymethylpropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-hydroxypropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-isopropoxy-propylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-methoxymethylpropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-methoxypropylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-2-propylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-4-hydroxybutylamino]-1H-quinolin-4-one
-
-
2-[3-(3,4-dichlorobenzylamino)-propylamino]-1H-quinolin-4-one
-
-
2-[3-[(3,4-dichlorobenzyl)amino]propoxy]quinolin-4(1H)-one
2-[3-[bis-(3,4-dichlorobenzyl)-amino]-2-dimethylamino-propylamino]-1H-quinolin-4-one
-
-
2-[[2-([[2-(benzyloxy)naphthalen-1-yl]methyl]amino)ethyl]amino]ethan-1-ol
-
-
2-[[3-(benzylamino)propyl]amino]quinolin-4(1H)-one
-
9.0% inhibition at 50 nM
2-[[5-(3,5-dichlorophenyl)pentyl]amino]quinazolin-4(1H)-one
-
-
3,5-dichloro-N-((1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)piperidin-3-yl)methyl)aniline
-
3,5-dichloro-N-[3-[(4-oxo-1,4-dihydroquinazolin-2-yl)amino]propyl]benzene-1-sulfonamide
-
-
3-(1,4-dihydro-2H-3,1-benzoxazin-2-yl)-4H-1-benzopyran-4-one
-
-
3-(1H-benzimidazol-1-yl)-N-benzylpropan-1-amine
-
-
3-(1H-benzimidazol-1-yl)-N-[(3,5-dimethoxyphenyl)methyl]propan-1-amine
-
-
3-(1H-benzimidazol-1-yl)-N-[(4-bromophenyl)methyl]propan-1-amine
-
-
3-(1H-benzimidazol-1-yl)-N-[(4-chlorophenyl)methyl]propan-1-amine
-
-
3-(1H-benzimidazol-1-yl)-N-[(4-methoxyphenyl)methyl]propan-1-amine
-
-
3-(5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecan-2-yl)-4H-chromen-4-one
-
-
3-(5-chloro-1H-benzo[d]imidazol-2-yl)-N-(3,5-dichlorobenzyl)cyclohexanamine
-
3-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N-(3,5-dichlorobenzyl) cyclohexanamine
-
3-(5-chloro-3H-imidazo [4,5-b] pyridin-2-yl)-N-(3,5-dichlorobenzyl)propan-1-amine
-
3-(6-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-yl)-4H-1-benzopyran-4-one
-
-
3-(6-chloro-1H-benzo[d]imidazol-2-yl)-N-(3,5-dichlorobenzyl) propan-1-amine
-
3-(6-methyl-1,4-dihydro-2H-3,1-benzoxazin-2-yl)-4H-1-benzopyran-4-one
-
-
3-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-1,4-dihydronaphthalen-1-ol
3-[([3-[(4-oxo-1,4-dihydroquinolin-2-yl)amino]propyl]amino)methyl]benzonitrile
-
20.2% inhibition at 50 nM
3-[[(4-chloronaphthalen-1-yl)oxy]methyl]piperidine
-
-
4'-((2-butyl-4-chloro-5-(5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecan-2-yl)-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carbonitrile
-
-
4'-[(3-[5-[4-(hydroxymethyl)phenyl]-1-oxa-3-azaspiro[5.5]undecan-2-yl]-2,3-dihydro-1H-indol-1-yl)methyl][1,1'-biphenyl]-2-carbonitrile
-
-
4'-[[3-(1,4-dihydro-2H-3,1-benzoxazin-2-yl)-1H-indol-1-yl]methyl][1,1'-biphenyl]-2-carbonitrile
-
-
4-(1,4-dihydro-2H-3,1-benzoxazin-2-yl)phenol
-
-
4-(1H-benzimidazol-2-yl)-N-[(2-chloro-6-fluorophenyl)methyl]aniline
-
-
4-(1H-benzimidazol-2-yl)-N-[(3-chlorophenyl)methyl]aniline
-
-
4-(1H-benzimidazol-2-yl)-N-[(4-chlorophenyl)methyl]aniline
-
-
4-(5-(4-methoxyphenyl)-1-oxa-3-azaspiro[5.5]undecan-2-yl)-N,Ndimethylaniline
-
-
4-(6-chloroquinolin-2-yl)aniline
-
-
4-(7-chloro-1,4-dihydro-2H-3,1-benzoxazin-2-yl)phenol
-
-
4-methoxybenzyloxy-quinoline
4-[(E)-[([[N-(thiophen-2-ylcarbonyl)glycyl]amino]methyl)imino]methyl]benzoic acid
-
structure molecular modeling, binding mode, detailed overview
4-[3-(3,4-dichlorobenzylamino)propylamino]-1H-quinolin-2-one
-
-
4-[4-[(1H-benzimidazol-2-ylmethyl)amino]-6-(2-chloro-4-methoxyphenoxy)pyrimidin-2-yl]piperazin-2-one
-
5-(4-methoxyphenyl)-2-(2-methyl-1H-indol-3-yl)-1-oxa-3-azaspiro[5.5]undecane
-
-
5-(4-methoxyphenyl)-2-(2-phenyl-1H-indol-3-yl)-1-oxa-3-azaspiro[5.5]undecane
-
-
5-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-b]pyridin-7(4H)-one
5-([3-[(6,8-dibromo-3,4-dihydro-2H-1-benzopyran-4-yl)amino]propyl]amino)thieno[3,2-b]pyridin-7(4H)-one
-
-
5-chloro-2-(1-(3,5-dichlorophenethyl)piperidin-3-yl)-1H-imidazo[4,5-b]pyridine
-
6-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-b]pyridin-4(7H)-one
6-chloro-2-(1H-indol-3-yl)-1,4-dihydro-2H-3,1-benzoxazine
-
-
6-chloro-2-(2-phenyl-1H-indol-3-yl)-1,4-dihydro-2H-3,1-benzoxazine
-
-
6-methyl-2-(2-methyl-1H-indol-3-yl)-1,4-dihydro-2H-3,1-benzoxazine
-
-
6-methyl-2-(2-phenyl-1H-indol-3-yl)-1,4-dihydro-2H-3,1-benzoxazine
-
-
9-(3-[(E)-[(3,5-dimethoxyphenyl)methylidene]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[(E)-[(4-bromophenyl)methylidene]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[(E)-[(4-chlorophenyl)methylidene]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[(E)-[(4-methoxyphenyl)methylidene]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[[(3,5-dimethoxyphenyl)methyl]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[[(4-bromophenyl)methyl]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[[(4-chlorophenyl)methyl]amino]propyl)-9H-purin-6-amine
-
-
9-(3-[[(4-methoxyphenyl)methyl]amino]propyl)-9H-purin-6-amine
-
-
9-[3-(benzylamino)propyl]-9H-purin-6-amine
-
-
9-[3-[(E)-benzylideneamino]propyl]-9H-purin-6-amine
-
-
actinomycin D
-
inhibits the nucleolar located enzyme due to dependence on polymerase I
adenosine
-
maximal inhibition at MgCl2 concentration from 4.0 mM to 10 mM, effective inhibition at high concentration of diphosphate
alpha-Amanitin
-
inhibits the nucleolar located enzyme due to dependence on polymerase I
benzoic acid 1-[(3,4-dichlorobenzylamino)-methyl]-2-(4-oxo-1,4-dihydroquinolin-2-ylamino)-ethyl ester
-
-
cisplatin
-
inhibits the nucleolar located enzyme due to dependence on polymerase I
ester analogues of L-methionyl adenylate
-
overview, modeling of interaction with the active site
Ethionine
-
methionyl-tRNA formation
hydroxamate analogues of L-methionyl adenylate
-
overview, modeling of the interaction with the active site
iodoacetamide
-
10 mM, weak
isovanilloid analogues of L-methionyl adenylate
-
overview, containing ribose biooisosteres
L-6,6,6-trifluoronorleucine
L-methionine analogue, competitive
L-cis-alpha-crotylglycine
L-methionine analogue, competitive
L-methionine hydroxamate
-
substrate analogue, inhibition mechanism, no inhibition of mutant T10M
L-norleucine
L-methionine analogue, competitive
L-norvaline
L-methionine analogue, competitive
L-trans-alpha-crotylglycine
L-methionine analogue, competitive
methionine
-
selenomethionyl-tRNA formation
N-(1,4-dihydroquinolin-2-yl)-N'-(2,3,5-trichlorobenzyl)propane-1,3-diamine
N-(1H-benzimidazol-2-yl)-N'-(3,5-dichlorobenzyl)propane-1,3-diamine
-
N-(3,5-dibromobenzyl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
N-(3-[[(2,5-dichlorothiophen-3-yl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(3-[[(2-methyl-1-benzothiophen-3-yl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-(2-hydroxyphenyl)urea
-
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-(3-hydroxyphenyl)urea
-
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-phenylurea
-
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
N-(3-[[(3-chloro-5-methoxyphenyl)methyl]amino]propyl)-N'-phenylurea
N-(3-[[(3-chloro-5-methoxyphenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(3-[[(3-cyanophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(3-[[(5-chloro-2-ethoxy-3-iodophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(3-[[(5-chloro-2-hydroxyphenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
N-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(2,4-dibromo-6-ethoxybenzyl)propane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(2,4-dichloro-6-ethoxybenzyl)propane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(2-bromo-4-chloro-6-ethoxybenzyl)propane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(2-bromo-6-ethoxy-4-methoxybenzyl)propane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(3,5-dibromobenzyl)propane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine
N-1H-benzimidazol-2-yl-N'-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine
N-[(3,5-dichlorophenyl)methyl]-3-[(4-oxo-1,4-dihydroquinazolin-2-yl)amino]propanamide
-
-
N-[(4R)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
N-[(4S)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
N-[3-([[2-(benzyloxy)-5-chloro-3-(prop-2-en-1-yl)phenyl]methyl]amino)propyl]-N'-thiophen-3-ylurea
-
N-[3-([[5-chloro-2-hydroxy-3-(prop-2-en-1-yl)phenyl]methyl]amino)propyl]-N'-thiophen-3-ylurea
-
N-[3-[(1H-benzimidazol-2-yl)amino]propyl]-3-(trifluoromethoxy)benzamide
-
-
N-[3-[([5-chloro-3-(prop-2-en-1-yl)-2-[(prop-2-en-1-yl)oxy]phenyl]methyl)amino]propyl]-N'-thiophen-3-ylurea
-
N-[[(1R)-2-[[(4,6-dichloro-1H-indol-2-yl)methyl]amino]cyclopentyl]methyl]-1H-benzimidazol-2-amine
-
-
N1-(1H-benzimidazol-2-yl)-N3-(6,8-dichloro-3,4-dihydro-2H-1-benzopyran-4-yl)propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[(3,5-dichloro-2-ethoxyphenyl)methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[(3,5-dichlorophenyl)methyl]propane-1,3-diamine
-
N1-(1H-benzimidazol-2-yl)-N3-[(3,6-dichloro-1H-indol-2-yl)methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[(3-bromo-2-ethoxy-5-methylphenyl)methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[(3-bromo-5-chloro-2-ethoxyphenyl)methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[(4,6-dichloro-3-methyl-1H-indol-2-yl)methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[(4,7-dichloro-1H-indol-2-yl)methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[[4,6-bis(trifluoromethyl)-1H-indol-2-yl]methyl]propane-1,3-diamine
-
-
N1-(1H-benzimidazol-2-yl)-N3-[[6-methoxy-4-(trifluoromethyl)-1H-indol-2-yl]methyl]propane-1,3-diamine
-
-
N1-(5-chloro-1H-imidazo[4,5-b]pyridin-2-yl)-N2-[(3,5-dichlorophenyl)methyl]-N1-methylethane-1,2-diamine
-
N1-(5-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-N2-(3,5-dichlorobenzyl) ethane-1,2-diamine
-
N1-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N3-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
-
-
N1-(6-chloro-1H-benzo[d]imidazol-2-yl)-N2-(3,5-dichlorobenzyl)ethane-1,2-diamine
-
N1-[(3,5-dibromophenyl)methyl]-N3-(7-methoxy-1H-benzimidazol-2-yl)propane-1,3-diamine
-
-
N1-[(3,5-dichloro-4-propylphenyl)methyl]-N3-(3H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
-
-
N1-[(4,5-dibromo-3-methylthiophen-2-yl)methyl]-N3-(3H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
-
-
N1-[(4,6-dimethyl-1H-indol-2-yl)methyl]-N3-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
-
-
N1-[(5-bromo-2-ethoxy-3-methoxyphenyl)methyl]-N3-(1H-imidazo[4,5-b]pyridin-2-yl)propane-1,3-diamine
-
-
N1-[[4-bromo-5-(1-fluoroethenyl)-3-methylthiophen-2-yl]methyl]-N3-(1H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
-
-
N1-[[4-bromo-5-(difluoromethyl)-3-methylthiophen-2-yl]methyl]-N3-(1H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
-
-
N1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-N3-(1H-imidazo[4,5-c]pyridin-2-yl)-2-propylpropane-1,3-diamine
-
-
N1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-N3-(3H-imidazo[4,5-c]pyridin-2-yl)propane-1,3-diamine
-
-
NH4+
-
ATP-diphosphate exchange
p-chloromercuribenzoate
-
-
Periodate-oxidized ATP
-
-
-
Periodate-oxidized tRNA
-
-
-
RNase
-
inhibits the nucleolar located enzyme due to dependence on rRNA
-
selenomethionine
-
methionyl-tRNA formation
vanilloid analogues of L-methionyl adenylate
-
overview, containing ribose biooisosteres
[1-[(3,4-dichlorobenzylamino)-methyl]-2-(4-oxo-1,4-dihydroquinolin-2-ylamino)ethyl]-carbamic acid tert-butyl ester
-
-
[2-[([3-[(1H-benzimidazol-2-yl)amino]propyl]amino)methyl]-4,6-dichlorophenyl]methanol
-
-
[3-(1H-benzimidazol-2-yl)piperidin-1-yl](2-methyl-1-benzofuran-5-yl)methanone
78% and 20% inhibition at 0.1 and 0.01 mM, respectively
[3-[4-(4-Methoxy-benzyloxy)-quinolin-2-ylsulfanyl]-propyl]-carbamic acid tert-butyl ester
1,10-phenanthroline

-
little or no inhibition by 1,7-phenanthroline and 4,7-phenanthroline
1,10-phenanthroline
-
complete inhibition of the cytoplasmic isozyme at 1 mM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is 0.0035 mM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 40 nM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is 0.099 mM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 170 nM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is 0.0066 mM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 340 nM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is 0.0035 mM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 18 nM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is 0.0013 mM
1-[1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 180 nM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is above 0.001 mM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 87 nM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is 0.0031 mM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-butyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 760 nM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is above 0.1 mM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-ethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 1670 nM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is 0.099 mM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 170 nM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is 0.0059 mM
1-[1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-propyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 850 nM
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is above 0.1 mM
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 70 nM
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-3-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
-
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-3-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-4-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
-
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-4-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is above 0.1 mM
1-[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 680 nM
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is above 0.1 mM
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-azetidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 510 nM
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-3-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-3-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-4-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-4-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
-
1-[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 1100 nM
1-[2-(4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
-
1-[2-(4-dichloro-phenyl)-5-oxo-oxazol-4-ylidenemethyl]-piperidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
-
1-[3-[(3,5-dibromobenzyl)amino]propyl]-3-phenylurea

-
-
1-[3-[(3,5-dibromobenzyl)amino]propyl]-3-phenylurea
-
IC50 is 330 nM
1-[[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is 0.027 mM
1-[[2-(2,4-dichloro-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 430 nM
1-[[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide

-
IC50 is 0.0061 mM
1-[[2-(4-bromo-phenyl)-5-oxo-oxazol-4-ylidene]-phenyl-methyl]-pyrrolidine-2-carboxylic acid [1-carbamoyl-2-(4-hydroxy-phenyl)-ethyl]-amide
-
IC50 is 810 nM
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-4H-chromen-4-one

-
-
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-4H-chromen-4-one
-
IC50 is 0.001 mM
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one

-
-
2-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
IC50 is below 0.3 nM
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one

-
-
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is 9.7 nM
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one

-
-
2-([3-[(2,4-dibromo-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is 4.9 nM
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one

-
-
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is below 3 nM
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one

-
-
2-([3-[(2,4-dichloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is below 3 nM
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one

-
-
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is below 3 nM
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one

-
-
2-([3-[(2-bromo-4-chloro-6-ethoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is below 3 nM
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one

-
-
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is 7.0 nM
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one

-
-
2-([3-[(2-bromo-6-ethoxy-4-methoxybenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is 3.3 nM
2-([3-[(3,4-dichlorobenzyl)amino]propyl]thio)quinolin-4(1H)-one

-
-
2-([3-[(3,4-dichlorobenzyl)amino]propyl]thio)quinolin-4(1H)-one
-
IC50 is 680 nM
2-([3-[(3,5-dibromo-2-ethoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one

-
98.2% inhibition at 50 nM
2-([3-[(3,5-dibromo-2-ethoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
2-([3-[(3,5-dibromo-2-methoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one

-
95.0% inhibition at 50 nM
2-([3-[(3,5-dibromo-2-methoxybenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one

-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one
-
IC50 is 580 nM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1H-indole-3-carbonitrile

-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-1H-indole-3-carbonitrile
-
IC50 is 54 nM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-6-phenylpyrimidin-4(1H)-one

-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)-6-phenylpyrimidin-4(1H)-one
-
IC50 is 0.001 mM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinazolin-4(1H)-one

-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is 8.1 nM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinolin-4(1H)-one

-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
IC50 is below 3 nM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)quinolin-4(1H)-one
-
98.8% inhibition at 50 nM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-d]pyrimidin-4(1H)-one

-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-d]pyrimidin-4(1H)-one
-
IC50 is 150 nM
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one

-
-
2-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is 3.9 nM
2-([3-[(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one

-
-
2-([3-[(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is 14 nM
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one

-
-
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is 8.2 nM
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one

-
-
2-([3-[(7-bromo-5-chloro-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is below 3 nM
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one

-
-
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)quinazolin-4(1H)-one
-
IC50 is 17 nM
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one

-
-
2-([3-[(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)amino]propyl]amino)thieno[3,2-d]pyrimidin-4(1H)-one
-
IC50 is below 3 nM
2-chloro-4-[(4-methoxybenzyl)oxy]quinoline

-
-
2-chloro-4-[(4-methoxybenzyl)oxy]quinoline
-
-
2-[3-[(3,4-dichlorobenzyl)amino]propoxy]quinolin-4(1H)-one

-
-
2-[3-[(3,4-dichlorobenzyl)amino]propoxy]quinolin-4(1H)-one
-
IC50 is 38 nM
3-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-1,4-dihydronaphthalen-1-ol

-
-
3-([3-[(2,3,5-trichlorobenzyl)amino]propyl]amino)-1,4-dihydronaphthalen-1-ol
-
IC50 is 0.0018 mM
4-methoxybenzyloxy-quinoline

-
-
4-methoxybenzyloxy-quinoline
-
-
5-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-b]pyridin-7(4H)-one

-
-
5-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[3,2-b]pyridin-7(4H)-one
-
IC50 is 4 nM
6-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-b]pyridin-4(7H)-one

-
-
6-([3-[(3,5-dibromobenzyl)amino]propyl]amino)thieno[2,3-b]pyridin-4(7H)-one
-
IC50 is 6.2 nM
ATP

-
substrate inhibition
N-(1,4-dihydroquinolin-2-yl)-N'-(2,3,5-trichlorobenzyl)propane-1,3-diamine

-
-
N-(1,4-dihydroquinolin-2-yl)-N'-(2,3,5-trichlorobenzyl)propane-1,3-diamine
-
IC50 is 0.0001 mM
N-(3,5-dibromobenzyl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine

-
-
N-(3,5-dibromobenzyl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
IC50 is 5.0 nM
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea

-
N-(3-[[(3,5-dichlorophenyl)methyl]amino]propyl)-N'-thiophen-3-ylurea
-
N-(3-[[(3-chloro-5-methoxyphenyl)methyl]amino]propyl)-N'-phenylurea

-
N-(3-[[(3-chloro-5-methoxyphenyl)methyl]amino]propyl)-N'-phenylurea
-
N-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine

-
-
N-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
-
N-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
IC50 is 11 nM
N-(6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
-
N-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine

-
-
N-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
IC50 is 18 nM
N-1H-benzimidazol-2-yl-N'-(2,4-dibromo-6-ethoxybenzyl)propane-1,3-diamine

-
-
N-1H-benzimidazol-2-yl-N'-(2,4-dibromo-6-ethoxybenzyl)propane-1,3-diamine
-
IC50 is 17 nM
N-1H-benzimidazol-2-yl-N'-(2,4-dichloro-6-ethoxybenzyl)propane-1,3-diamine

-
-
N-1H-benzimidazol-2-yl-N'-(2,4-dichloro-6-ethoxybenzyl)propane-1,3-diamine
-
IC50 is below 3 nM
N-1H-benzimidazol-2-yl-N'-(2-bromo-4-chloro-6-ethoxybenzyl)propane-1,3-diamine

-
-
N-1H-benzimidazol-2-yl-N'-(2-bromo-4-chloro-6-ethoxybenzyl)propane-1,3-diamine
-
IC50 is 3.8 nM
N-1H-benzimidazol-2-yl-N'-(2-bromo-6-ethoxy-4-methoxybenzyl)propane-1,3-diamine

-
-
N-1H-benzimidazol-2-yl-N'-(2-bromo-6-ethoxy-4-methoxybenzyl)propane-1,3-diamine
-
IC50 is 17 nM
N-1H-benzimidazol-2-yl-N'-(3,5-dibromobenzyl)propane-1,3-diamine

-
-
N-1H-benzimidazol-2-yl-N'-(3,5-dibromobenzyl)propane-1,3-diamine
-
IC50 is 29 nM
N-1H-benzimidazol-2-yl-N'-(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine

-
-
N-1H-benzimidazol-2-yl-N'-(5,7-dibromo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine
-
IC50 is 14 nM
N-1H-benzimidazol-2-yl-N'-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine

-
-
N-1H-benzimidazol-2-yl-N'-(7-ethyl-5-iodo-1,2,3,4-tetrahydroquinolin-4-yl)propane-1,3-diamine
-
IC50 is 16 nM
N-[(4R)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine

-
-
N-[(4R)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
IC50 is 6.3 nM
N-[(4S)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine

-
-
N-[(4S)-6,8-dibromo-1,2,3,4-tetrahydroquinolin-4-yl]-N'-1H-imidazo[4,5-b]pyridin-2-ylpropane-1,3-diamine
-
IC50 is 48 nM
REP3123

-
active against a collection of 108 clinical isolates of Clostridium difficile and against epidemic, moxifloxacin-resistant BI/NAP1/027 strains
REP3123
a selective and potent competitive, versus methionine not ATP, MetRS inhibitor, that strongly binds at the active site, docking study
REP8839

-
-
[3-[4-(4-Methoxy-benzyloxy)-quinolin-2-ylsulfanyl]-propyl]-carbamic acid tert-butyl ester

-
-
[3-[4-(4-Methoxy-benzyloxy)-quinolin-2-ylsulfanyl]-propyl]-carbamic acid tert-butyl ester
-
-
additional information

MetRS drug design and homology modelling, overview
-
additional information
-
MetRS drug design and homology modelling, overview
-
additional information
-
structure-activity relationships of inhibitor derived from an oxazolone-dipeptide scaffold
-
additional information
-
antibacterial potency of the inhibitors, structure-activity relationships, inhibition mechanism, the quinolone moiety of the right hand side pharmacophore is crucial for enzyme inhibition, overview
-
additional information
-
inhibition mechanism, the quinolone moiety of the right hand side pharmacophore is crucial for enzyme inhibition, overview
-
additional information
-
large scale MetRS inhibitor screening, diverse compounds, overview
-
additional information
-
structure-activity relationships of inhibitor derived from an oxazolone-dipeptide scaffold
-
additional information
-
antibacterial potency of the inhibitors, structure-activity relationships, inhibition mechanism, the quinolone moiety of the right hand side pharmacophore is crucial for enzyme inhibition, overview
-
additional information
-
in vitro minimum inhibitory concentrations of quinoline compounds with different strains of Staphylococcus aureus, structure-activity relationships
-
additional information
-
inhibitor screening, hstructures, omology modeling, molecular docking studies, and computational development of pharmacophore models, overview; inhibitor screening, structures, homology modeling, molecular docking studies, and computational development of pharmacophore models, overview
-
additional information
-
inhibition mechanism, the quinolone moiety of the right hand side pharmacophore is crucial for enzyme inhibition, overview
-
additional information
-
a homology model of the Trypanosoma brucei MetRS based on other MetRS structures is used to model binding of lead diaryl diamine compounds in the design and development of selective parasite MetRS inhibitors for treatment of African trypanosomiasis, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.